^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    INGN 225

    i
    Other names: INGN 225, Ad.p53 DC vaccine, adenovirus-p53 transduced dendritic cell vaccine, autologous dendritic cell adenovirus p53 vaccine, INGN-225
    Associations

    News

    Trials
    Company:
    Lumos Pharma
    Drug class:
    p53 stimulant
    Related drugs:
    Associations

    News

    Trials
    1year
    Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
    P2, N=14, Terminated, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Dec 2023 --> May 2022 | Active, not recruiting --> Terminated; Sponsor closed study
    Trial completion date • Trial termination
    |
    TP53 (Tumor protein P53)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • INGN 225
    almost2years
    Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
    P2, N=14, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Apr 2022 --> Dec 2022
    Trial primary completion date
    |
    TP53 (Tumor protein P53) • IFNG (Interferon, gamma)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • INGN 225
    over2years
    Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
    P2, N=14, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Dec 2021 --> Apr 2022
    Clinical • Trial primary completion date
    |
    TP53 (Tumor protein P53) • IFNG (Interferon, gamma)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • INGN 225
    almost3years
    Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
    P2, N=14, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Apr 2024 --> Dec 2023 | Trial primary completion date: Apr 2022 --> Dec 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • IFNG (Interferon, gamma)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • INGN 225